Literature DB >> 9395331

Effects of brefeldin A on phosphatidylcholine phospholipase D and inositolphospholipid metabolism in HL-60 cells.

I Guillemain1, J H Exton.   

Abstract

The involvement of the small GTP-binding protein ADP-ribosylation factor (ARF) in guanosine 5'-[gamma-thio]triphosphate (GTP[S])-dependent activation of phospholipase D (PLD) in HL-60 cells has been well established in vitro. In this study, we tested the effect of brefeldin A, which prevents ARF activation by inhibiting guanine-nucleotide-exchange activity, on PLD stimulation by receptor agonists (formyl-Met-Leu-Phe and ATP) and by the phorbol ester phorbol 12-myristate 13-acetate (PMA) in differentiated HL-60 cells. However, brefeldin A did not affect the activation of PLD at a time (1 h) when it eliminated the activity of the trans-Golgi enzyme galactosyltransferase. It also did not inhibit PLD activity in Golgi-enriched membranes treated with GTP[S] with or without ARF in vitro. However, longer times of brefeldin A treatment (>6 h), progressively and completely inhibited the activation of PLD by formyl-Met-Leu-Phe and partly inhibited (approximately 50%) the activation by PMA. In contrast, long-term brefeldin A treatment did not inhibit the effect of GTP[S] on PLD in permeabilized HL-60 cells. Long-term brefeldin A treatment completely inhibited inositol phosphate production in response to formyl-Met-Leu-Phe and ATP, indicating that it affected inositolphospholipid-specific phospholipase C activity. These data indicate that the rapid inhibitory effect of brefeldin A on Golgi function is not associated with inhibition of receptor-mediated or PMA-mediated PLD activation in HL-60 cells. However, longer-term effects, presumably arising from the disruption of the Golgi, lead to a total inhibition of agonist activation of PLD and inositolphospholipid-specific phospholipase C. In summary, these results do not support a role for brefeldin-A-sensitive ARF in agonist regulation of PLD in HL-60 cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395331     DOI: 10.1111/j.1432-1033.1997.00812.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  5 in total

1.  Elevated phospholipase D activity in H-Ras- but not K-Ras-transformed cells by the synergistic action of RalA and ARF6.

Authors:  Lizhong Xu; Paul Frankel; Desmond Jackson; Thuy Rotunda; Rita L Boshans; Crislyn D'Souza-Schorey; David A Foster
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

2.  Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.

Authors:  M Gorospe; J M Egan; B Zbar; M Lerman; L Geil; I Kuzmin; N J Holbrook
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  Overexpression of myristoylated alanine-rich C-kinase substrate enhances activation of phospholipase D by protein kinase C in SK-N-MC human neuroblastoma cells.

Authors:  S C Morash; S D Rosé; D M Byers; N D Ridgway; H W Cook
Journal:  Biochem J       Date:  1998-06-01       Impact factor: 3.857

4.  Inhibition of formyl peptide-stimulated phospholipase D activation by Fal-002-2 via blockade of the Arf6, RhoA and protein kinase C signaling pathways in rat neutrophils.

Authors:  Ya-Ru Tsai; Li-Jiau Huang; Hui-Yi Lin; Yun-Jie Hung; Miau-Rong Lee; Sheng-Chu Kuo; Mei-Feng Hsu; Jih-Pyang Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-03-23       Impact factor: 3.000

5.  Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP).

Authors:  Tze-chen Hsieh; Peili Wu; Spencer Park; Joseph M Wu
Journal:  BMC Complement Altern Med       Date:  2006-09-11       Impact factor: 3.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.